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Rod C Scott†, Richard F Chin†, on behalf of the North London Epilepsy Research Network‡
Summary
Background The prognosis of convulsive status epilepticus (CSE), a common childhood medical neurological 
emergency, is not well characterised. We aimed to investigate the long-term outcomes in a cohort of participants who 
previously had CSE.
Methods In this prospective study, we followed up a population-based childhood CSE cohort from north London, UK 
(the north London convulsive status epilepticus surveillance study cohort; NLSTEPSS). We collected data from 
structured clinical neurological assessment, neurocognitive assessment (Wechsler Abbreviated Scale of Intelligence), 
brain MRI, medical records, and structured interviews with participants and their parents to determine neurological 
outcomes, with adverse outcome defined as presence of one or more of epilepsy (active or in remission), motor 
disability, intellectual disability, or statement of special educational needs. We applied multiple imputation to address 
missing data and performed binary logistic regression analyses on complete-case and imputed datasets to investigate 
sociodemographic and CSE factors associated with adverse outcomes. 
Findings Of 203 survivors (90% of inception cohort), 134 (66%) were assessed at a median follow-up of 8·9 years 
(IQR 8·2–9·5). The cumulative incidence of epilepsy was 24·7% (95% CI 16·2–35·6), with most (89%) emerging 
within 18 months after CSE. The cumulative incidence of epilepsy was lower in patients with prolonged febrile 
seizures (14·3%, 6·3–29·4) and survivors of acute symptomatic CSE (13·3%, 3·7–37·9) than in those of remote 
symptomatic CSE (45·5%, 21·3–72·0) and unclassified CSE (50·0%, 25·4–74·6). One participant (2·9%, 0·5–14·5) 
in the prolonged febrile seizures group developed temporal lobe epilepsy with mesial temporal sclerosis. The absence 
of fever at CSE was the only predictor of incident epilepsy (odds ratio [OR] 7·5, 95% CI 2·25–25·1). Motor and 
intellectual disability was seen predominantly in participants who had idiopathic and cryptogenic CSE (seven [36·8%, 
95% CI 19·1–59·0] and 16 [84·2%, 62·4–94·5] of 19, respectively) and remote symptomatic CSE (33 [62·3%, 
48·8–74·1] and 40 [75·5%, 62·4–85·1] of 53), and most of these participants had pre-existing disabilities. Pre-existing 
epilepsy was the only predictor of intellectual disability (OR 8·0, 95% CI 1·1–59·6). 51·5% (95% CI 43·1–59·8) of 
those followed up had a statement of special educational needs.
Interpretation Childhood CSE is associated with substantial long-term neurological morbidity, but primarily in those 
who have epilepsy, neurological abnormalities, or both before the episode of CSE. Survivors without neurological 
abnormalities before CSE have favourable outcomes.
Funding BUPA Foundation, The Academy of Medical Sciences, Wellcome Trust, National Institute for Health 
Research, and Young Epilepsy.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license. 
Introduction
Convulsive status epilepticus (CSE), a common 
childhood medical neurological emergency, is 
associated with increased mortality and morbidity, but 
there is considerable variability in reported frequency 
of adverse outcomes.1,2 Between 11% and 45% of 
patients develop new-onset epilepsy within 5 years after 
CSE, but most studies do not separate motor and 
cognitive sequelae. Although some evidence suggests 
that short-term hippocampal injury and developmental 
or memory impairments occur after febrile status 
epilepticus, whether these changes lead to development 
of mesial temporal sclerosis is uncertain.2–5 Most 
outcome studies are constrained by methodological 
shortcomings such as hospital-based or retrospective 
designs, unclear definition of outcomes, lack of formal 
neurocognitive assessment and neuroimaging, small 
sample size, and short follow-up (usually only up to 
5 years). Thus, prognosis after childhood CSE is not 
well characterised.2
We did the first population-based study focused on 
childhood CSE, the north London convulsive status epi-
lepticus surveillance study (NLSTEPSS), and described 
incidence, cause, and short-term outcomes.1 We 
followed up these participants in this Status Epilepticus 
Outcomes Study (STEPSOUT). Having previously 
published data for risk and predictors of death,6 we aimed 
to comprehensively assess this cohort to investigate their 
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long-term epilepsy, motor, intellectual, and educational 
outcomes after CSE. 
Methods
Study design and participants
Recruitment for NLSTEPSS has previously been 
reported.1 In summary, between May 1, 2002, and 
April 30, 2004, using a multitiered notification system set 
up within a collaborative network of 21 hospitals in north 
London (UK), 226 participants with CSE were enrolled. 
Clinical and demographic data were shared with the 
central research team using linked anonymisation.
For STEPSOUT, participants were recruited through 
their local paediatricians, who used individual unique 
NLSTEPSS identification to recall patient identifiable 
information and determine survival status.6 All surviving 
participants from NLSTEPSS were eligible for inclusion. 
Local paediatricians sent an invitation letter to these 
participants or their parents (if participant was still younger 
than 18 years) on behalf of the research team, with study 
information and consent forms, asking them to consent 
for study participation. Non-responders were sent 
reminders before being considered lost to follow-up.
We obtained written informed consent from all 
participant’s parents or guardians, and consent or assent 
from each participant. STEPSOUT was approved by the 
UCL Institute of Child Health and Great Ormond Street 
Hospital Research Ethics Committee. We report our 
study findings according to STROBE guidelines. 
Procedures
For each participant, background demographic, medical, 
and developmental data before CSE, and clinical details 
about CSE were obtained from the NLSTEPSS database. 
Research in context
Evidence before this study
A previous systematic review on outcomes of childhood 
convulsive status epilepticus (CSE) included papers published 
up to May, 2006. We performed an additional search on 
PubMed for original articles on outcomes after childhood CSE 
published between June 1, 2006, and July 31, 2017, with the 
search terms “status epilepticus” combined with the terms 
“outcome”, “morbidity”, “prognosis”, “recurrence”, “mesial 
temporal sclerosis”, “hippocampal sclerosis”, and “cognition”. 
Searches were repeated with “prolonged febrile convulsion”, 
“prolonged febrile seizure”, and “lengthy febrile seizure”. Only 
studies that included patients aged between 1 month and 
18 years at the time of status epilepticus were considered. 
The search identified 32 relevant additional articles. From the 
results of the systematic review and more recent studies it is 
clear that childhood CSE is associated with increased mortality 
and morbidity; however, there is considerable variability in 
reported frequency of adverse outcomes, primarily because of 
methodological differences. Also, evidence suggests short-term 
hippocampal injury and developmental or memory 
impairments after febrile status epilepticus, but whether these 
changes lead to development of mesial temporal sclerosis is 
uncertain. Most previous studies are hospital based or 
retrospective and have a small sample size or short follow-up 
(up to 5 years); therefore, whether the existing literature can be 
generalised to understand the natural history and prognosis 
following childhood CSE is uncertain.
Added value of this study
After reporting the incidence, cause, and short-term outcomes 
from children in the north London convulsive status epilepticus 
surveillance study (NLSTEPSS), we prospectively followed up 
this cohort to determine their long-term outcomes. To our 
knowledge, this is the first prospective population-based study 
to comprehensively describe the natural history and the 
long-term outlook after childhood CSE due to all causes. 
Our results showed that although morbidity is considerable 
after childhood CSE, this is seen primarily in those with 
symptomatic causes and pre-existing neurological 
abnormalities. Previously neurologically normal children have a 
favourable outcome with low incidence of epilepsy, motor 
disability, and intellectual disability after CSE. CSE recurrence 
occurs predominantly in those with previous neurological 
abnormalities. We also showed that temporal lobe epilepsy and 
mesial temporal sclerosis can be seen after all forms of 
childhood CSE, not just prolonged febrile seizures, but are 
uncommon. Our data suggest that CSE characteristics such as 
seizure duration are not major predictors of outcome 
independently of cause.
Implications of all the available evidence
Collectively, the available data are reassuring and suggest 
favourable outcomes in previously neurologically normal 
children, and the direct contribution of CSE in the development 
of neurological sequelae seems less than previously thought. 
However, whether CSE results in subtle neurocognitive deficits 
or behavioural difficulties in previously neurologically normal 
children is uncertain and needs investigation. Studies 
comparing outcomes after short seizures with seizures lasting 
30 min or longer might also help to determine whether early 
cessation of seizures might improve outcomes. Development 
of strategies for early identification of those at high risk of 
neurocognitive sequelae and appropriate support at school and 
behavioural support might reduce the long-term negative 
effects of childhood CSE and improve quality of life. In addition 
to improvements in acute management of seizures, reducing 
childhood CSE incidence through preventive measures such as 
universal immunisation and optimal management of epilepsy, 
particularly in resource-poor settings, offers the best 
opportunity to reduce the morbidity and mortality associated 
with childhood CSE.
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To investigate prognosis and predictors of adverse 
outcomes after CSE, we retained the NLSTEPSS CSE 
classification.1,7 Baseline motor functioning was deter-
mined from clinical neurological assessment at hospital 
discharge after initial CSE. Because formal cognitive 
assessment could not be performed at CSE for pragmatic 
reasons, we used parental report on development 
milestones before CSE occurred. We defined baseline 
cognition as abnormal if there was previously diagnosed 
intellectual disability, or if there was develop mental delay 
documented in two or more domains: motor, speech or 
language, cognition, social or personal, or activities of 
daily living.8
Participants and their parents were interviewed, using 
a structured pro forma to ensure systematic and 
consistent enquiry for presence of seizures or epilepsy 
(before and after CSE and at follow-up), seizure 
semiology and epilepsy course, CSE recurrence, 
cognitive and motor development, behav ioural 
problems, and schooling. Interviews were supple mented 
with review of hospital records. Participants underwent 
structured clinical neurological assessment (done by 
SSP) and neurocognitive assessment using the Wechsler 
Abbreviated Scale of Intelligence (WASI; done by 
MMM), and were invited to have brain MRI on an 
Avanto 1.5 Tesla scanner (Siemens, Erlangen, Germany). 
A single consent was used for all assessments including 
MRI. All participants were encouraged to undergo MRI 
but parents had the option to opt out if they did not wish 
to have MRI. Conventional MRI sequences, fluid 
attenuated inversion recovery (FLAIR), and three-
dimensional fast low angle shot (3D-FLASH) sequences 
were acquired for detailed visualisation of mesial 
temporal structures. Mesial temporal sclerosis was 
defined radiologically as the presence of definite 
hippocampal atrophy, increased T2 signal in the 
hippocampus, and disturbed internal architecture.9 All 
scans were visually analysed and reported by experienced 
paediatric neuroradiologists, as per standard clinical 
practice. All scans were further reviewed by another 
experienced paediatric neuroradiologist (WKKC), who 
was masked to clinical details. 
Outcomes
Our primary objective was to assess epilepsy, motor, 
intellectual, and educational outcomes in survivors after 
childhood CSE. The secondary objectives were to estimate 
cumulative incidence, incidence, predictors, and spectrum 
of new-onset (incident) epilepsy; describe prevalence of 
epilepsy (active and in remission) and predictors of active 
epilepsy; estimate cumulative incidence, incidence, and 
predictors of incident motor and intellectual disability; 
describe prevalence of motor and intellectual disability, 
and educational difficulties; determine CSE recurrence; 
and characterise brain MRI findings.
Data from interviews, medical records, and neurology 
and neurocognitive assessments were used to determine 
outcomes. Adverse neurological outcomes were defined 
as having one or more of the following: epilepsy (active 
or in remission), motor disability, intellectual disability, 
or a statement of special educational needs (table 1). We 
adopted the International League Against Epilepsy 
(ILAE) guidelines for epilepsy definitions and classi-
fication, and an adaptation of the 2001 WHO Global 
Burden of Disease (GBD) project for definitions of motor 
and cognitive outcomes.10,11 Need for special educational 
support determined educational outcomes.
Statistical analysis
Analyses were done by two authors (SSP and MC-B) 
using R software environment for statistical computing 
(version 3.0.1) for multiple imputation, SPSS (version 21.0) 
for subsequent statistical analyses, including Kaplan-
Meier analysis, and StatXact (version 4, Cytel Software) 
to calculate the exact difference in proportions in char-
acteristics between study participants and those lost to 
follow-up.
We calculated cumulative incidence for each adverse 
outcome by dividing total new-onset (incident) cases by 
the total number of cases without adverse outcome at 
baseline and available for follow-up. We determined 
incidence by dividing total incident cases by person-years 
in the population without adverse outcome at baseline 
and available for follow-up. We calculated 95% CIs on the 
basis of the Poisson distribution. Because most 
participants were at preschool age (1 month to 5 years) at 
CSE presentation, we did not calculate incidence for 
adverse educational outcomes. We calculated prevalence 
Definition
Seizures or epilepsy
Epilepsy Two or more unprovoked seizures occurring at least 24 h apart
Terminal remission Seizure-free and off drug treatment in the preceding 2 years
Active epilepsy Seizures within the past 2 years or currently on drug treatment for epilepsy
CSE recurrence Recurrence of one or more episodes of CSE during follow-up (ie, between 
entry into NLSTEPSS and end of follow-up in the current study)
Motor functioning
Minor impairment Isolated hypotonia, gait, or coordination difficulties
Motor disability Spasticity or paresis of one or more limbs (eg, cerebral palsy, hemiparesis)
Intellectual functioning
Normal Full-scale IQ score of 85 or above on WASI
Borderline intellectual functioning Full-scale IQ score between 71 and 84 on WASI
Intellectual disability Full-scale IQ score of 70 or lower on WASI, or untestable because of 
profound impairment
Educational difficulties
Additional support in 
mainstream class
Special educational needs met effectively within mainstream settings 
through additional support (eg, School Action or School Action Plus)
Statement of special educational 
needs
Children with a statutory statement of special educational needs requiring 
substantial additional support in school because of learning, medical, 
or behavioural difficulties
CSE=convulsive status epilepticus. NLSTEPSS=the north London convulsive status epilepticus surveillance study. 
WASI=the Wechsler Abbreviated Scale of Intelligence.
Table 1: Definitions for clinical outcomes at follow-up
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of each outcome as the pro portion of the cohort with 
adverse outcome at follow-up.
To investigate predictors of incident epilepsy, active 
epilepsy, incident motor disability, and incident intel-
lectual disability, we used a complete-case approach for 
participants with complete baseline and follow-up data. 
We applied multivariate imputation by chained 
equations (MICE) to address missing data and minimise 
potential bias.12 We performed binary logistic regression 
analyses on complete-case and imputed datasets. We 
used univariable analyses to identify factors reaching 
statistical significance of p≤0·1, which were then 
assessed in multivariable analyses. Factors not 
significant on univariable analyses were included in 
final models to identify factors associated with adverse 
outcomes only after adjustment for other clinically 
relevant variables. Socio demographic variables included 
age at CSE, sex, prematurity (gestation <37 weeks), 
family history of epilepsy, and Index of Multiple 
Deprivation 2004 (IMD 2004) scores as indicators of 
socioeconomic status. Clinical variables were previous 
febrile seizures, first-ever (incident) versus previous 
CSE, febrile (temperature >38°C) versus afebrile CSE, 
whether prehospital treatment for CSE was given, 
interval between onset and first treatment for CSE, 
duration of CSE (continuous and categorical variable), 
intermittent versus continuous, type of seizure onset 
(focal vs generalised), and epilepsy, motor disability, or 
abnormal cognition at baseline.
Role of the funding source
The funders of the study had no role in the study design, 
data collection, data analysis, data interpretation, the 
writing of the report, or in the decision to submit the 
paper for publication. The corresponding author had full 
access to all the data in the study and had final 
responsibility for the decision to submit for publication.
Results
Of 203 surviving participants (90% of inception cohort in 
NLSTEPSS), 20 (10%) could not be contacted, 
49 (24%) declined consent, and 134 (66%) were 
followed up (figure 1). 67 (50%) participants in the 
follow-up study were boys and 67 (50%) were girls, 
median age was 2·7 years (IQR 1·1–5·1) at CSE and 
11·6 years (9·8–14·3) at follow-up. Median CSE duration 
was 70 min (IQR 45–100), and median follow-up was 
8·9 years (IQR 8·2–9·5). There was no significant 
difference in clinical or demographic characteristics 
between STEPSOUT participants and dropouts 
(appendix). At follow-up, all 134 participants had in-
person neurological examination; 94 underwent neuro-
cognitive evaluation and the remaining 40 were not 
assessable using WASI due to profound cognitive 
impairment and were therefore categorised as having 
intellectual disability. MRI data were available for 
106 (79%) participants. The rest were either unable to 
co-operate for MRI scan because of intellectual disability 
or behavioural problems, or declined consent.
The cumulative incidence of epilepsy was 24·7% 
(95% CI 16·2–35·6) and incidence was 28·8 (95% CI 
17·1–45·6) per 1000 person-years (table 2). Cumulative 
incidence was lower in prolonged febrile seizures 
(14·3%, 95% CI 6·3–29·4) and acute symptomatic CSE 
(13·3%, 3·7–37·9) than in remote symptomatic CSE 
(45·5%, 21·3–72·0) and unclassified CSE (50·0%, 
25·4–74·6). All incident epilepsies emerged within 5 years 
after CSE, 89% within 18 months (figure 2). In the 
complete-case analysis, absence of fever at CSE was the 
only predictor of incident epilepsy (odds ratio [OR] 7·5, 
95% CI 2·25–25·1) and results were similar in the 
multiple imputation analysis (appendix)
Of the five participants with prolonged febrile seizures 
and with incident epilepsy, one developed temporal lobe 
epilepsy (4·5 years later) and had mesial temporal 
sclerosis (appendix). Two participants with unclassified 
CSE and one with remote symptomatic CSE developed 
temporal lobe epilepsy, and all except one (who declined 
MRI) had mesial temporal sclerosis. Thus, one (2·9%) of 
35 participants with prolonged febrile seizures and four 
(5·5%) of 73 participants with no epilepsy before CSE 
226 recruited during NLSTEPSS
56 prolonged febrile seizures
30 acute symptomatic CSE
28 idiopathic epilepsy-related CSE
9 cryptogenic epilepsy-related CSE
88 remote symptomatic CSE
15 unclassified CSE
23 deaths
7 within 30 days of CSE
16 during follow-up
203 survivors eligible for follow-up in STEPSOUT 
56 prolonged febrile seizures
26 acute symptomatic CSE
28 idiopathic epilepsy-related CSE
6 cryptogenic epilepsy-related CSE
72 remote symptomatic CSE
15 unclassified CSE
69 were not followed up
20 could not be contacted
49 declined consent
134 participated in follow-up study
35 prolonged febrile seizures
15 acute symptomatic CSE
15 idiopathic epilepsy-related CSE
4 cryptogenic epilepsy-related CSE
53 remote symptomatic CSE
12 unclassified CSE
Figure 1: Study flow diagram
CSE=convulsive status epilepticus. NLSTEPSS=the north London convulsive 
status epilepticus surveillance study. STEPSOUT=Status Epilepticus Outcomes 
Study.
See Online for appendix
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developed temporal lobe epilepsy, with or without mesial 
temporal sclerosis, after CSE.
Prevalence of epilepsy was 59·0% (95% CI 50·5–66·9) 
(table 3). Active epilepsy was present in 
55 (41%) participants, primarily in those who had 
idiopathic and cryptogenic CSE, remote symptomatic 
CSE, and none who had prolonged febrile seizures 
(table 3). All five participants in the prolonged febrile 
seizures group who developed epilepsy after CSE were 
seizure free and off drug treatment in the preceding 
2 years before the follow-up visit. In complete-case 
multivariable analysis, having epilepsy before CSE was 
the only predictor of active epilepsy at follow-up (OR 8·4, 
95% CI 1·8–39·0), with similar results in the multiple 
imputation analysis (appendix). No one with prolonged 
febrile seizures was later diagnosed with Dravet 
syndrome.
Cumulative incidence of motor disability was 
2·1% (95% CI 0·6–7·4) and of intellectual disability was 
8·8% (4·3–17·0), and incidence was 2·5 (95% CI 
0·3–9·0) per 1000 person-years and 10·2 (4·1–21·1) per 
1000 person-years, respectively (table 2). Because only 
two incident cases occurred, we did not do regression 
analysis for motor disability. In complete-case analysis, 
pre-existing epilepsy at CSE was the only predictor of 
intellectual disability (OR 8·0, 95% CI 1·1–59·6), with 
similar results in the multiple imputation analysis 
(appendix). No participants in the prolonged febrile 
seizure and acute symptomatic CSE groups developed 
motor disability, and one participant who had prolonged 
febrile seizures developed intellectual disability.
Motor and intellectual disability was seen predomi-
nantly in participants with remote symptomatic CSE and 
those with idiopathic and cryptogenic CSE. Of 
19 participants with idiopathic and cryptogenic CSE, 
motor disability was seen in seven (36·8%, 95% CI 
19·1–59·0) and intellectual disability in 16 (84·2%, 
62·4–94·5), reflecting pre-existing disabilities in 36·8% 
and 68·4%, respectively. Of 53 participants with remote 
symptomatic CSE, 33 (62·3%, 48·8–74·1) had motor 
disability and 40 (75·5%, 62·4–85·1) had intellectual 
disability (table 3), with pre-existing disabilities in 60·4% 
and 71·7%, respectively. 59 (92·2%, 95% CI 83·0–96·6) of 
64 participants with motor disability, intellectual 
disability, or both, also had epilepsy (appendix).
In the entire cohort, 80 (59·7%, 95% CI 51·2–67·6) 
received educational support, and 69 (51·5%, 43·1–59·8)
had a statement of special education needs (appendix). 
Two (5·7%, 1·6–18·6) participants with prolonged febrile 
seizures and none (0%, 0–20·4) of those with acute 
symptomatic CSE had a statement of special educational 
needs, compared with 17 (89·5%, 68·6–97·1) participants 
with idiopathic and cryptogenic CSE and 46 (86·8%, 
75·2–93·5) participants with remote symptomatic CSE. 
Participants who had already had previous CSE at entry 
to NLSTEPSS were 4·5 times (95% CI 1·8–11·1) more 
likely to have CSE recurrence during follow-up than those 
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whose initial CSE was their first episode (appendix). 
Participants with pre-existing neurological abnormalities 
were 3·8 times (95% CI 1·8–8·0) more likely to have 
recurrence than those without. Ten (28·6%) participants 
with prolonged febrile seizures had recurrence; of these, 
four had epilepsy after CSE and the other six did not have 
any further seizures or epilepsy.
Of 59 participants with no pre-existing neurological 
abnormality, 50 (85%) underwent MRI; and of 
75 participants with pre-existing neurological 
abnormality, 53 (71%) had MRI, either for the study or 
had had recent MRI for clinical reasons and were 
adequate for our review. Thus, participants with 
neurological abnormalities or abnormal MRI are not 
overrepresented in neuroimaging results.
Of 32 participants with prolonged febrile seizures who 
had MRIs, two (6·25%, 95% CI 1·7–20·1) had clinically 
significant abnormalities. One participant with temporal 
lobe epilepsy had unilateral mesial temporal sclerosis 
and another participant who was neurologically normal 
had MRI features of neurofibromatosis type 1. Of 
41 participants with remote symptomatic CSE who had 
MRI, 31 (75·6%, 60·7–86·2) had significant structural 
abnormalities. 31 (83·8%, 68·9–92·4) of 37 participants 
with clinically significant MRI abnormalities had 
epilepsy with or without other neurological comorbidity 
(appendix).
Discussion
In this prospective study, we investigated long-term 
seizure incidence and neurological morbidity at a median 
follow-up of 8·9 years in survivors of a population-based 
childhood CSE cohort. Our main findings are that most 
participants with no previous neurological abnormality 
do not develop epilepsy, motor, or intellectual disability 
after CSE, and have a favourable outcome. Subsequent 
temporal lobe epilepsy and mesial temporal sclerosis can 
be found after all forms of CSE, not just prolonged febrile 
seizures, but are uncommon. Additionally, participants 
with epilepsy, neurological abnormality, or both, before 
CSE had high risk of intellectual disability, and often 
have active epilepsy at follow-up. The outcome after CSE 
depends mainly on its cause, and participants with 
clinically significant abnormal MRIs were at the highest 
risk for adverse outcomes. Finally, CSE recurrence 
occured predominantly in those with previous 
neurological abnormalities, and CSE duration does not 
have prognostic significance for any of the outcomes.
Cumulative incidence of epilepsy in our cohort (25%) is 
similar to the 23–36% incidence reported in studies with 
shorter follow-up.2,13–15 This result is partly because almost 
90% of our cohort who developed epilepsy did so within 
18 months after CSE. 10% of children with incident 
epilepsy present with CSE as their first unprovoked 
seizure and 80–90% of recurrences happen within 
2 years after a first unprovoked seizure.16,17 Thus, unpro-
voked CSE, like brief seizures, could be the presentation 
that leads to the diagnosis of epilepsy within 2 years and 
a low risk thereafter.
Our results further support previous data showing 
good short-term and long-term neurological outcomes in 
children with prolonged febrile seizures.2,15,18–23 14% of 
participants with prolonged febrile seizure in our cohort 
developed epilepsy, all with good seizure outcome, and 
only one participant had intellectual disability. Our 
findings, together with reports from FEBSTAT showing 
acute hippocampal injury and subtle cognitive 
impairment within 1 year.3–5 suggest the possibility of 
short-term hippocampal involvement but with minimal 
long-term consequences. Data are conflicting on the 
causative role of prolonged febrile seizures in later 
development of mesial temporal sclerosis and temporal 
lobe epilepsy.2,23–26 Our data suggest that temporal lobe 
epilepsy is not common (3%) in those who develop 
epilepsy after prolonged febrile seizures, and prevalence 
of mesial temporal sclerosis is low (3%) within 9 years 
after prolonged febrile seizures. These findings are 
consistent with observations from earlier prospective 
studies sug gesting low incidence of temporal lobe 
epilepsy (<6%) and mesial temporal sclerosis (<7%) after 
pro longed febrile seizures.18,22,23,25,26 Although prolonged 
febrile seizures might increase risk of hippocampal 
injury in those with pre-existing abnormalities, the direct 
contribution of prolonged febrile seizures in development 
of mesial temporal sclerosis, temporal lobe epilepsy, 
or both, seems less than has long been believed.4,26
In our study, prevalence of motor disability was 31% and 
intellectual disability was 46%. However, disabilities were 
seen mostly in participants with idiopathic and 
cryptogenic CSE and those with remote symptomatic 
Number at risk
(number censored)
Prolonged febrile seizures
Acute symptomatic CSE
Remote symptomatic CSE
Unclassifed CSE
All CSE
0
35 (0)
16 (0)
13 (0)
12 (0)
76 (0)
0 (30)
1 (13)
0 (7)
0 (6)
1 (56)
  16 (14)
8 (6)
4 (3)
4 (2)
  32 (25)
29 (1)
13 (1)
6 (1)
5 (1)
53 (4)
30 (0)
13 (1)
6 (1)
6 (0)
55 (2)
31 (0)
14 (0)
6 (1)
6 (0)
57 (1)
31 (0)
14 (0)
6 (1)
7 (0)
58 (1)
Follow-up (months)
0
20 40 60 80 100 120
0·2
0·4
0·6
0·8
1·0
Cu
m
ul
at
iv
e 
pr
ob
ab
lit
y o
f e
pi
le
ps
y
Remote symptomatic CSE
Unclassifed CSE
Acute symptomatic CSE
Prolonged febrile seizures
Figure 2: Kaplan-Meier graph for prevalence of epilepsy at CSE presentation (baseline) and incident epilepsy 
during follow-up, by CSE category 
All participants in idiopathic and cryptogenic CSE group by definition had epilepsy at CSE presentation, and 
therefore the line is not visible in the graph. CSE=convulsive status epilepticus.
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CSE. Additionally, disabilities were present before CSE in 
most participants, and fewer than 9% were incident. The 
incidence of motor and intellectual disability in 
STEPSOUT are broadly consistent with the reported 
incidence of less than 20%, but there are two notable 
variances in the subgroup findings.2,15,18,19,21 One is the 
seemingly high incidence of intellectual disability in the 
idiopathic and cryptogenic CSE group, with three of 
six participants who were reported to be developmentally 
normal at CSE presentation performing within intellectual 
disability range on neurocognitive testing. Although the 
point estimate in this subgroup with modest sample size 
is high at 50%, the 95% CI is wide (19–81%) and overlaps 
with results reported in previous literature. Possible 
reasons for this finding include differences in classification 
(we classified idiopathic and cryptogenic epilepsy-related 
CSE and unclassified CSE separately, whereas unclassified 
CSE are grouped under idiopathic CSE group in most 
previous studies and therefore the reported outcomes are 
better); we used a formal cognitive assessment, whereas 
other studies could have missed some participants who 
might not have had formal testing; and our study had a 
longer follow-up compared with other studies and the 
probability of detection of abnormalities increases with 
time.27 The second difference is that our point estimate of 
0% for permanent motor and intellectual disability for 
surviving participants after acute symptomatic CSE is 
lower than that in some previous studies.2 Given the width 
of the 95% CI (0·0–20·4) of this modest sized subgroup 
(n=15), the true estimate might be more consistent with a 
higher incidence of disabilities. However, it is equally 
possible that the true estimate is closer to our point 
estimate and would be consistent with other studies in 
which acute symptomatic CSE is associated with increased 
short-term mortality and the neurological outcome among 
survivors is favourable.15,28,29 The 60% of participants who 
needed educational support were mostly among those 
who had neurological problems before CSE, and this 
proportion is similar to the 63% reported in school-aged 
children with active epilepsy.27 Taken together, our data 
suggest that CSE itself might not independently increase 
the risk of long-term neurocognitive sequelae in a major 
way.
Our findings provide strong population-based data 
suggesting the cause of childhood CSE is the main 
determinant of long-term outcome after the event.2,15,23 
Incidence of neurological sequelae is high in those with 
symptomatic causes and pre-existing neurological 
abnormalities, and seemingly low in previously 
neurologically normal children. In addition to cause, 
other CSE-related characteristics such as younger age at 
CSE, absence of fever, focal seizure onset, history of 
seizures or CSE, and seizure duration have commonly 
been associated with poor outcomes.2 However, because 
it is extremely difficult to separate the effect of CSE itself 
from its cause, which influences seizure characteristics 
such as duration, their additional effect on subsequent 
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outcomes is uncertain.2 Our findings are consistent with 
those from earlier studies, and suggest that CSE 
characteristics such as seizure duration are not major 
predictors of outcome independent of underlying 
cause.14,15,18,26,28,30 However, by definition, only children with 
seizures longer than 30 min were included in our study.1,31 
This raises the question if earlier cessation of seizures 
would result in decreased morbidity and mortality.
Data from our group and others suggest that CSE is 
associated with acute brain injury and short-term 
cognitive impairment, with at least partial recovery as a 
result of brain plasticity and reorganisation during 
follow-up.3–5,32 We speculate that children with 
pre-existing brain pathology (structural or genetic) 
might have less reserve and thus less chance of recovery, 
which might explain the major contribution of cause to 
outcomes. Some evidence also suggests that repeated 
CSE are associated with worse outcomes.7 Thus, in 
theory, earlier cessation of seizures might result in better 
outcomes, particularly in children who already have 
neurological problems or have had previous CSE. 
Studies comparing outcomes after short seizures with 
seizures lasting longer than 30 min might provide useful 
information, but would still be confounded by the 
severity of the underlying brain disorder and might not 
be able to determine the independent effect of CSE on 
outcomes. Therefore, ready access to emergency 
treatment, parti cularly for high-risk groups, should be 
considered.
Although our study has the advantage of prospective, 
long-term follow-up of a large population-based cohort, 
it has limitations. Loss to follow-up is inevitable in 
epidemiological studies and the reported follow-up 
rates for cohort studies are typically lower than 
60% after 5 years.33 With our best efforts we could 
follow up 66% of the original cohort, which is not 
surprising given the duration of follow-up and 
population migration for residents in London, and 
acceptable for this type of study. Our data show no 
significant difference in the demographic and clinical 
characteristics of the follow-up cohort and those lost to 
follow-up (appendix). Additionally, we applied multiple 
imputation to address missing data and minimise 
potential bias, and found the results to be consistent 
using both complete-case and multiple imputation 
approaches.12 Therefore, we are confident that the 
chances that our results are biased are very low. 
However, multiple imputation is based on the 
assumption that data are missing at random, and there 
is no way to know whether outcomes of participants 
who could not be followed up were systematically 
different from those that we included in the follow-up. 
Thus, the potential bias due to multiple imputation 
cannot be measured. Because the latency to the 
development of temporal lobe epilepsy and mesial 
temporal sclerosis after prolonged febrile seizures 
could be even longer than our follow-up duration, it is 
possible we might not have captured all cases.24 
Moreover, results from this study, done in a high-
income country, might not be generalisable to 
resource-poor settings where the population have poor 
access to emergency medical care, suboptimal intensive 
care facilities, and a different spectrum of CSE causes. 
For example, the majority of  childhood CSE cases in 
Kenya were caused by infection.34 
To conclude, the results of our prospective population-
based study showed that childhood CSE is associated 
with substantial long-term neurological morbidity, but 
primarily in those who have epilepsy or neurological 
abnormalities before CSE. Children without pre-existing 
neurological abnormalities who survived CSE have 
favourable outcomes.
Author contributions
SP, MDH, CG, BGN, RCS, and RFC designed the study. SP and MMM 
collected data. SP and MC-B did the statistical analysis. WKKC analysed 
the MRI scans. All authors contributed to interpretation and writing the 
manuscript. BGN passed away before submission of the manuscript.
Members of the North London Epilepsy Research Network
Suresh Pujar, Brian Neville, Rod Scott, Richard Chin 
(UCL Great Ormond Street Institute of Child Health, London, UK); 
Jacqueline Taylor, Simon Roth (Barnet and Chase Farm Hospital, 
London, UK); Ruby Schwartz (Central Middlesex Hospital, London, UK); 
Edwin Abrahamson (Chelsea and Westminster Hospital, London, UK); 
Elaine Hughes (Evelina Children’s and King’s College Hospital, both in 
London, UK); Jackie Bucknall, Rajiv Sood (Homerton Hospital London, 
UK); MAS Ahmed (Queen’s Hospital, London, UK); Satheesh Mathew 
(Newham General Hospital, London, UK); Arvind Shah (North 
Middlesex Hospital, London, UK); Caroline Oren (Northwick Park 
Hospital, London, UK); Dulmini Birkett, Michael Greenberg (Royal Free 
Hospital, London, UK); Adelaida Martinez (Royal London Hospital, 
London, UK); Simon Nadel (St Mary’s Hospital, London, UK); 
Corina O’Neill (Whipps Cross Hospital, London, UK); and 
Andrew Robins (Whittington Hospital, London, UK).
Declaration of interests
RS reports grants from the BUPA Foundation, during the conduct of 
the study. RFC reports grants from the BUPA Foundation, The 
Academy of Medical Sciences and Wellcome Trust, and the UK National 
Institute for Health Research Biomedical Research Centre at Great 
Ormond Street Hospital for Children NHS Foundation Trust and 
University College London; salary funding from Young Epilepsy; and 
personal fees from Special Products Limited and Shire Pharmaceuticals 
during the conduct of the study; as well as personal fees from Eisai 
Pharmaceuticals and GW Pharma outside the submitted work. SSP was 
supported by funding from Young Epilepsy. Other authors declare no 
competing interests.
Acknowledgments
This research was funded by grants from the BUPA Foundation 
(BUPA 22094612), The Academy of Medical Sciences and Wellcome 
Trust (SGCL1Chin), and the UK National Institute for Health Research 
Biomedical Research Centre at Great Ormond Street Hospital for 
Children NHS Foundation Trust and University College London. SSP 
was supported by funding from Young Epilepsy. We thank the members 
of the North London Epilepsy Research Network for their help in 
identifying and recruiting children for the study.
References
1 Chin RF, Neville BG, Peckham C, Bedford H, Wade A, Scott RC. 
Incidence, cause, and short-term outcome of convulsive status 
epilepticus in childhood: prospective population-based study. 
Lancet 2006; 368: 222–29.
2 Raspall-Chaure M, Chin RF, Neville BG, Scott RC. Outcome of 
paediatric convulsive status epilepticus: a systematic review. 
Lancet Neurol 2006; 5: 769–79.
Articles
www.thelancet.com/child-adolescent   Vol 2   February 2018 111
3 Scott RC, King MD, Gadian DG, Neville BG, Connelly A. 
Hippocampal abnormalities after prolonged febrile convulsion: 
a longitudinal MRI study. Brain 2003; 126: 2551–57.
4 Shinnar S, Bello JA, Chan S, et al. MRI abnormalities following 
febrile status epilepticus in children: the FEBSTAT study. 
Neurology 2012; 79: 871–77.
5 Weiss EF, Masur D, Shinnar S, et al. Cognitive functioning one 
month and one year following febrile status epilepticus. 
Epilepsy Behav 2016; 64: 283–88.
6 Pujar SS, Neville BG, Scott RC, Chin RF. Death within 8 years after 
childhood convulsive status epilepticus: a population-based study. 
Brain 2011; 134: 2819–27.
7 Berg A, Shinnar S, Testa F, et al. Status epilepticus after the initial 
diagnosis of epilepsy in children. Neurology 2004; 63: 1027–34.
8 Shevell M, Ashwal S, Donley D, et al. Practice parameter: evaluation 
of the child with global developmental delay report of the Quality 
Standards Subcommittee of the American Academy of Neurology 
and The Practice Committee of the Child Neurology Society. 
Neurology 2003; 60: 367–80.
9 Malmgren K, Thom M. Hippocampal sclerosis—origins and 
imaging. Epilepsia 2012; 53: 19–33.
10 Thurman DJ, Beghi E, Begley CE, et al. Standards for epidemiologic 
studies and surveillance of epilepsy. Epilepsia 2011; 52: 2–26.
11 Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, 
Rudan I. Global and regional risk of disabling sequelae from 
bacterial meningitis: a systematic review and meta-analysis. 
Lancet Infect Dis 2010; 10: 317–28.
12 Van Buuren S, Groothuis-Oudshoorn, K. Mice: multivariate 
imputation by chained equations in R. J Statistical Software 2011; 
45: 1–67.
13 Aicardi J, Chevrie JJ. Convulsive status epilepticus in infants and 
children. A study of 239 cases. Epilepsia 1970; 11: 187–97.
14 Barnard C, Wirrell E. Does status epilepticus in children cause 
developmental deterioration and exacerbation of epilepsy? 
J Child Neurol 1999; 14: 787–94.
15 Maytal J, Shinnar S, Moshe SL, Alvarez LA. Low morbidity and 
mortality of status epilepticus in children. Pediatrics 1989; 
83: 323–31.
16 Berg AT. Risk of recurrence after a first unprovoked seizure. 
Epilepsia 2008; 49: 13–18.
17 Berg AT, Shinnar S, Levy SR, Testa FM. Status epilepticus in 
children with newly diagnosed epilepsy. Ann Neurol 1999; 
45: 618–23.
18 Nelson KB, Ellenberg JH. Prognosis in children with febrile 
seizures. Pediatrics 1978; 61: 720–77.
19 Shinnar S, Pellock JM, Berg AT, et al. Short-term outcomes of 
children with febrile status epilepticus. Epilepsia 2001; 42: 47–53.
20 Verity CM, Greenwood R, Golding J. Long-term intellectual and 
behavioral outcomes of children with febrile convulsions. 
N Engl J Med 1998; 338: 1723–28.
21 Verity CM, Ross EM, Golding J. Outcome of childhood status 
epilepticus and lengthy febrile convulsions: findings of national 
cohort study. BMJ 1993; 307: 225–28.
22 Chungath M, Shorvon S. The mortality and morbidity of febrile 
seizures. Nat Clin Pract Neurol 2008; 4: 610–21.
23 Verity CM. Do seizures damage the brain? The epidemiological 
evidence. Arch Dis Child 1998; 78: 78–84.
24 Patterson KP, Baram TZ, Shinnar S. Origins of temporal lobe 
epilepsy: febrile seizures and febrile status epilepticus. 
Neurotherapeutics 2014; 11: 242–50.
25 Tarkka R, Paakko E, Pyhtinen J, Uhari M, Rantala H. Febrile 
seizures and mesial temporal sclerosis: no association in a 
long-term follow-up study. Neurology 2003; 60: 215–18.
26 Lewis DV, Shinnar S, Hesdorffer DC, et al. Hippocampal sclerosis 
after febrile status epilepticus: the FEBSTAT study. Ann Neurol 2014; 
75: 178–85.
27 Reilly C, Atkinson P, Das KB, et al. Academic achievement in 
school-aged children with active epilepsy: a population-based study. 
Epilepsia 2014; 55: 1910–17.
28 Hussain N, Appleton R, Thorburn K. Aetiology, course and outcome 
of children admitted to paediatric intensive care with convulsive 
status epilepticus: a retrospective 5-year review. Seizure 2007; 
16: 305–12.
29 Kravljanac R, Jovic N, Djuric M, Jankovic B, Pekmezovic T. 
Outcome of status epilepticus in children treated in the intensive 
care unit: a study of 302 cases. Epilepsia 2011; 52: 358–63.
30 Shinnar S, Berg AT, Moshe SL, et al. The risk of seizure recurrence 
after a first unprovoked afebrile seizure in childhood: an extended 
follow-up. Pediatrics 1996; 98: 216–25.
31 Trinka E, Cock H, Hesdorffer D, et al. A definition and classification 
of status epilepticus—report of the ILAE Task Force on 
Classification of Status Epilepticus. Epilepsia 2015; 56: 1515–23.
32 Pujar SS, Seunarine KK, Martinos MM, Neville BGR, Scott RC, 
Chin RFM, et al. Long-term white matter tract reorganization 
following prolonged febrile seizures. Epilepsia 2017; 58: 772–80.
33 Fewtrell MS, Kennedy K, Singhal A, et al. How much loss to 
follow-up is acceptable in long-term randomised trials and 
prospective studies? Arch Dis Child 2008; 93: 458–61.
34 Sadarangani M, Seaton C, Scott JA, et al. Incidence and outcome of 
convulsive status epilepticus in Kenyan children: a cohort study. 
Lancet Neurol 2008; 7: 145–50.
